ERBB2 and breast carcinoma: Numerous studies revealed that the survival time of breast cancer patients positively correlated with tumor-infiltrating lymphocytes (TILs), particularly in HER2+ and TNBC subtypes (Loi, 2013; Adams et al., 2014).